Efficacy, safety and immunogenicity study of GSK Biologicals’ candidate malaria vaccine (SB257049) evaluating schedules with or without fractional doses, early Dose 4 and yearly doses, in children 5-17 months of age

Trial Identifier: 204889
Sponsor: GlaxoSmithKline
Start Date: September 2017
Primary Completion Date: November 2019
Study Completion Date: November 2022
Condition: Parasite Infections

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Ghana Kumasi, Ghana, NONE
Kenya Kisumu, Kenya, 40100